Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

1.60USD
23 Feb 2018
Change (% chg)

$0.03 (+1.91%)
Prev Close
$1.57
Open
$1.60
Day's High
$1.60
Day's Low
$1.55
Volume
19,952
Avg. Vol
52,741
52-wk High
$5.99
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Cytrx reports strategic realignment of clinical development team
Monday, 6 Nov 2017 09:00am EST 

Nov 6 (Reuters) - Cytrx Corp ::Cytrx announces strategic realignment of clinical development team.Cytrx - announced ‍strategic realignment of drug development efforts for advancing new drug candidates based on ladr technology platform​.Cytrx Corp - co's drug development, manufacturing and regulatory activities will be led by Hurley Consulting Associates​.Cytrx Corp - ‍is poised to file INDS with FDA for one or more new ladr drug conjugates in 2018​.  Full Article

Cytrx Corp announces reverse stock split
Tuesday, 31 Oct 2017 09:00am EDT 

Oct 31 (Reuters) - Cytrx Corp :Cytrx Corporation announces reverse stock split.Cytrx Corp- ‍1-for-6 reverse​ stock split will become effective as of commencement of trading on Wednesday, November 1, 2017.  Full Article

Cytrx corp says ‍Nasdaq has granted co's request for a continued listing
Monday, 16 Oct 2017 08:20pm EDT 

Oct 16 (Reuters) - Cytrx Corp ::Cytrx corp - ‍Nasdaq has granted co's request for a continued listing pending results of a stockholder vote on or before October 30, 2017​.  Full Article

Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
Thursday, 12 Oct 2017 09:00am EDT 

Oct 12 (Reuters) - Cytrx Corp ::Cytrx Corporation highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions planned by Licensee Nantcell, Inc..  Full Article

CytRx Corp provides business update and highlights future plans
Monday, 2 Oct 2017 09:00am EDT 

Oct 2 (Reuters) - CytRx Corp :CytRx Corp provides business update and highlights future plans.CytRx Corp - hopes to nominate next Linker Activated Drug Release discovery platform candidate for clinical development by end of 2017.CytRx Corp - CytRx ended Q2 of 2017 with $55 million in cash.CytRx Corp - restructured and paid down $10 million of its existing debt during Q3.  Full Article

CytRx corp says Glass Lewis & Co recommends CytRx stockholders vote "for" proposed reverse stock split​
Thursday, 21 Sep 2017 09:00am EDT 

Sept 21 (Reuters) - CytRx Corp :CytRx Corp - proxy advisory firm Glass Lewis & Co. Recommends CytRx Corp stockholders vote "for" proposed reverse stock split​.  Full Article

CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting
Wednesday, 13 Sep 2017 09:00am EDT 

Sept 13 (Reuters) - CytRx Corp :CytRx Corp announces amendment to definitive proxy statement for upcoming special meeting.CytRx Corp - amended definitive proxy statement with SEC to include a 1-for-6 reverse stock split of company's authorized common and preferred stock​.  Full Article

Cytrx reports Q2 loss per share $0.10
Thursday, 3 Aug 2017 09:00am EDT 

Aug 3 (Reuters) - Cytrx Corp :Cytrx reports second quarter 2017 financial results.Q2 loss per share $0.10.Cytrx corp - ‍cash, cash equivalents and short-term investments of $55.0 million as of june 30, 2017​.  Full Article

Cytrx Corp announces Global Strategic License With Nantcell for Aldoxorubicin
Friday, 28 Jul 2017 09:00am EDT 

July 28 (Reuters) - Cytrx Corp ::CytRX Corporation announces global strategic license with Nantcell Inc for Aldoxorubicin, an albumin mediated chemotherapeutic.CytRX Corp - ‍under terms of license agreement, Nantcell made a strategic investment by purchasing $13 million of CytRX common stock at $1.10 per share.CytRX - entitled to receive up to additional $343 million in milestone payments related to regulatory approvals and commercial milestones for Aldoxorubicin​.CytRX -to get increasing double-digit royalties for sales of aldoxorubicin for soft tissue sarcomas, mid to high single digit royalties for other indications.CytRX Corp - ‍cytrx also issued nantcell a warrant to purchase up to 3 million shares of common stock at $1.10 over next 18 months.CytRX Corp - ‍nantcell will be responsible for all future development, manufacturing and commercialization expenses.CytRX- amended long-term loan facility, to make payment of $5 million to lender upon closing of global license, strategic investment for Aldoxorubicin​.  Full Article

Cytrx reports Q1 loss per share $0.10
Wednesday, 10 May 2017 09:00am EDT 

May 10 (Reuters) - Cytrx Corp :Cytrx reports first quarter 2017 financial results.Q1 loss per share $0.10.Cytrx corp - goal is to submit a rolling nda under section 505(b)(2) to FDA in Q4 of 2017 for aldoxorubicin.Cytrx Corp- commercial launch of aldoxorubicin is projected for 2018 in U.S.Cytrx Corp - Cytrx also plans to discuss with European Medicines Agency a path to filing a marketing authorization application. For aldoxorubicin.  Full Article

BRIEF-Cytrx announces new shareholder initiatives

* Cytrx Corporation provides business update and announces new shareholder initiatives